Medication info
SBIA Tablets 50 mg (Sitagliptin Hydrochloride Monohydrate)

SBIA Tablets 50 mg (Sitagliptin Hydrochloride Monohydrate)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tablet
Manufacturer / importer
Boryung Biopharma Co., Ltd.
Appearance
Pale yellow-pink, round, biconvex, film-coated tablet
Packaging
(30 tablets) 10 tablets/PTP (x3)
Approval status
Active

MFDS item code 202005816 · Approved 2020.08.14 · Insurance code 670502270

Summary

Main use
Improvement of blood glucose control in type 2 diabetes
Who takes it
Adults
Adult dose
Administer 100 mg once daily as monotherapy or combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dose adjustment according to renal function is required, assessment of renal function is recommended before starting this medicine and periodically during treatment. 1. No dose adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.

Ingredients

Manufacturer
Boryung Biopharma Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in type 2 diabetes

  • Type 2 diabetes
  • blood glucose control abnormalities
View approved original text

This medication is used in conjunction with diet and exercise to effectively control blood glucose in patients with type 2 diabetes. It can be administered alone if blood glucose control is manageable; however, it may be combined with metformin if there is no prior experience with diabetes pharmacotherapy or if monotherapy is insufficient. Additionally, if blood glucose control is inadequate with sulfonylurea, thiazolidinedione, or insulin monotherapy or in combination with metformin, this drug is added to assist with blood glucose management. Thus, it can be used either alone or in combination depending on the patient's situation for efficient blood glucose control.

How to take

Adult dose

Administer 100 mg once daily as monotherapy or combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dose adjustment according to renal function is required, assessment of renal function is recommended before starting this medicine and periodically during treatment. 1. No dose adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.

Precautions

This medication may cause serious allergic reactions in some patients; therefore, if any symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur after taking the medicine, discontinue immediately and consult a physician. It may induce pancreatitis, a condition characterized by inflammation of the pancreas; if symptoms such as abdominal pain, vomiting, or loss of appetite appear, inform healthcare professionals immediately. This drug should not be used in patients with type 1 diabetes or diabetic ketoacidosis, and those with a history of allergic reactions to the drug or its components should avoid its use. Patients with impaired kidney function may have difficulty excreting the drug, increasing the risk of side effects, so dosage adjustments according to physician directions and regular kidney function tests are necessary. During treatment with this drug, symptoms such as upper respiratory infection, nasopharyngitis, headache, diarrhea, nausea may occur, particularly when taken with insulin or sulfonylurea, where the risk of hypoglycemic symptoms may be more frequent, requiring careful monitoring of blood glucose levels. Severe joint pain or skin diseases with blistering may occur; if such symptoms appear, notify a physician immediately, and medication may need to be discontinued if necessary. It is not recommended for use in pregnant or breastfeeding women, and safety for children and adolescents under 18 years old has not been established. Elderly patients may be at risk of impaired kidney function, thus require dosage adjustments and kidney function tests. In case of overdose, general symptomatic treatment is provided, and blood dialysis may be helpful if needed, following the healthcare provider's instructions. This medication may increase the risk of hypoglycemia when used with other hypoglycemic agents, requiring careful dosage adjustments of concomitant medications. Finally, abnormal liver function, deteriorating kidney function, skin rash, muscle pain, and various side effects have been reported, and any abnormal symptoms should be promptly discussed with healthcare professionals.

Side effects

Anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, hypoglycemia, upper respiratory infection, nasopharyngitis, headache, diarrhea, abdominal pain, nausea, constipation, vomiting, severe joint pain accompanied by disability, vesicular pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevated liver enzymes, acute renal failure, pneumonia, diabetes complications, metabolic acidosis, falls, cardiac arrest, dyspepsia, dizziness, increased serum triglycerides, gastritis, increased low-density lipoprotein, hyperglycemia, weight loss, hypertension, hypernatremia, erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent air and moisture ingress, preferably at room temperature between 1 to 30 degrees Celsius. Proper storage maintains the effectiveness of the medication and prevents deterioration.

Appearance and packaging

Appearance

Pale yellow-pink, round, biconvex, film-coated tablet

Package unit

(30 tablets) 10 tablets/PTP (x3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.